Cinclus Pharma Holding Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OM:CINPHA Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Role	Shares	Max Price
04 Jun 26	BuySEK 157,300	Kajsa Larsson	Individual		13,000	SEK 12.10
11 Dec 25	BuySEK 496,834	Christer Ahlberg	Individual		29,000	SEK 17.13

Insider Trading Volume

Insider Buying: CINPHA insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of CINPHA?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	5,153,601	11.1%
Private Companies	7,091,921	15.2%
Institutions	13,245,261	28.5%
General Public	21,047,006	45.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 16 shareholders own 54.77% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
8%	Trill Impact Ventures Pharma 1 AB	3,721,221	SEK 45.7m	0%	no data
7.95%	Fourth Swedish National Pension Fund (AP4)	3,700,000	SEK 45.4m	0%	0.02%
5.01%	Movestic Fonder AB	2,329,632	SEK 28.6m	-1.47%	0.84%
4.98%	Linc AB	2,318,322	SEK 28.5m	0%	1.31%
4.49%	Peter Unge	2,090,015	SEK 25.7m	0%	no data
4.1%	Kjell Andersson	1,908,000	SEK 23.4m	0%	no data
3.58%	Futur Pension Försäkringsaktiebolag (publ.)	1,666,056	SEK 20.5m	0%	0.6%
3.37%	Estate Of Mikael Dahlström	1,569,613	SEK 19.3m	0%	no data
3.3%	Nordnet Pensionsförsäkring AB	1,536,841	SEK 18.9m	0%	0.21%
2.5%	Nylof Holding Ab	1,164,575	SEK 14.3m	0%	no data
2.33%	Lennart Hansson	1,084,771	SEK 13.3m	0%	no data
1.93%	Eir Ventures	898,750	SEK 11.0m	0%	100.0%
1.71%	Avanza Fonder AB	795,660	SEK 9.8m	0%	0.01%
1.37%	Postamentet Holding Ab	636,512	SEK 7.8m	0%	no data
0.12%	Jesper Wiklund	54,490	SEK 669.2k	27.1%	no data
0.035%	Kajsa Larsson	16,325	SEK 200.5k	391%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/10 10:40
End of Day Share Price	2026/08/07 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cinclus Pharma Holding AB (publ) is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ulrik Trattner	DNB Carnegie
Fredrik Thor	Redeye
Kevin Sule	Redeye